MK-7075
Total Payments
$646,849
Transactions
56
Doctors
11
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $646,849 | 56 | 11 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $628,772 | 28 | 97.2% |
| Travel and Lodging | $12,027 | 18 | 1.9% |
| Food and Beverage | $5,551 | 9 | 0.9% |
| Consulting Fee | $500.00 | 1 | 0.1% |
Payments by Type
Research
$628,772
28 transactions
General
$18,078
28 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1,2 Study of ARQ 092 Miransertib in Subjects with PIK3CA-related Overgrowth Spectrum and Proteus Syndrome | Merck Sharp & Dohme Corporation | $620,213 | 1 |
| An Open-label Phase 1b Study of ARQ 092 in Combination with Other Antineoplastic Agents in Subjects with Selected Solid Tumors | Merck Sharp & Dohme Corporation | $8,559 | 0 |
Top Doctors Receiving Payments for MK-7075
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Morrisville, NC | $625,497 | 27 |
| , MD | Pediatrics | Boston, MA | $3,275 | 1 |
| , M.D | Pediatric Hematology-Oncology | Cincinnati, OH | $2,023 | 3 |
| , M.D | Pediatrics | Peoria, IL | $2,019 | 3 |
| , MD | Pediatrics | Palo Alto, CA | $1,982 | 3 |
| , M.D | Pediatrics | New Brunswick, NJ | $1,964 | 3 |
| , M.D | Pediatrics | Chicago, IL | $1,961 | 3 |
| Jonathan Perkins | Otolaryngology | Seattle, WA | $1,936 | 3 |
| , MD | Clinical Genetics (M.D.) | Madison, WI | $1,935 | 3 |
| , MD | Pediatric Hematology-Oncology | Boston, MA | $1,893 | 3 |
| , DO | Hematology & Oncology | Atlanta, GA | $1,866 | 3 |
| , MD | Pediatric Dermatology | Milwaukee, WI | $500.00 | 1 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $646,849
Product Information
- Type Drug
- Total Payments $646,849
- Total Doctors 11
- Transactions 56
About MK-7075
MK-7075 is a drug associated with $646,849 in payments to 11 healthcare providers, recorded across 56 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2020 to 2020. In 2020, $646,849 was paid across 56 transactions to 11 doctors.
The most common payment nature for MK-7075 is "Unspecified" ($628,772, 97.2% of total).
MK-7075 is associated with 2 research studies, including "A Phase 1,2 Study of ARQ 092 Miransertib in Subjects with PIK3CA-related Overgrowth Spectrum and Proteus Syndrome" ($620,213).